<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05057130</url>
  </required_header>
  <id_info>
    <org_study_id>AMAP2021-7-2</org_study_id>
    <nct_id>NCT05057130</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Combination of Doxorubicin, Cisplatin and Methotrexate in Patients Aged 24-40 Years With Primary Bone Tumors</brief_title>
  <official_title>Neoadjuvant Three-component Chemotherapy Based on a Combination of Doxorubicin, Cisplatin and Methotrexate in Patients Aged 24-40 Years With Primary Bone Tumors to Increase the Response Rate Compared With Two-component Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Blokhin's Russian Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Blokhin's Russian Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Two cycles of neoadjuvant three-component chemotherapy according to the MAP prototoc:&#xD;
      Doxorubicin 25 mg / m2 IV on days 1-3, Cisplatin 120 mg / m2 IV on day 1 against the&#xD;
      background of hyperhydration. G-CSF support from 4 to 13 days. Methotrexate 12 g / m2 at 28&#xD;
      and 35 days IV with leucovorin 60 mg / m2 in the first 5 days after each administration of&#xD;
      methotrexate. The interval between cycles is 42 days.&#xD;
&#xD;
      The advantage of this regimen is to use the three-component chemotherapy regimen, which&#xD;
      should increase the degree of tumor necrosis and increase the rate of tumor response to&#xD;
      treatment, which will further improve the disease prognosis. Currently, the use of such&#xD;
      treatment for adult patients (over 24 years old) is controversial. Since it is believed that&#xD;
      the elimination of methotrexate in adult patients is more delayed than in patients under 24&#xD;
      years old, and can lead to serious adverse events (SAE). However, the use of modern standard&#xD;
      methods of hemodialysis makes it possible to avoid SAE.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The role of methotrexate in neoadjuvant chemotherapy for bone tumors is a topic for debate.&#xD;
      However, the benefits of methotrexate have been confirmed in at least one phase II study&#xD;
      showing better results with high doses of methotrexate in the context of triple chemotherapy.&#xD;
      Moreover, many studies have shown a correlation between peak serum methotrexate levels, tumor&#xD;
      response to chemotherapy, and treatment outcome. Thus, it is possible that the negative&#xD;
      results of the effectiveness of methotrexate have been compromised due to the administration&#xD;
      of insufficient doses or incorrect administration of the drug. The optimal regimen of&#xD;
      methotrexate administration has not been established. However, the control group in the&#xD;
      EURAMOS-1 study of the American Osteosarcoma Research Group (AOST) is considered as the&#xD;
      standard. The main practical problem with the use of triple chemotherapy in a group of&#xD;
      patients aged 24 and older is that the slow clearance of methotrexate can delay the&#xD;
      administration of the next cycle of doxorubicin-cisplatin, thereby reducing the dose&#xD;
      intensity and adversely affecting the outcome. Currently, there are both isolated clinical&#xD;
      cases and observations of a small number of included patients. The use of three-component&#xD;
      neoadjuvant chemotherapy for primary bone tumors will improve the rate of response to&#xD;
      treatment, reduce the frequency of recurenses and disease progression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of patients who have a partial or complete response to therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of tumor necrosis</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of tumor necrosis after chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of safety assessment</measure>
    <time_frame>6 months</time_frame>
    <description>Adverse Event Assessment and Serious Adverse Event Assessment according to CTCAE 5.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Osteosarcoma</condition>
  <condition>Neoplasms, Connective Tissue</condition>
  <condition>Neoplasms, Connective and Soft Tissue</condition>
  <condition>Sarcoma</condition>
  <condition>Sarcoma of Bone</condition>
  <arm_group>
    <arm_group_label>Three-component chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doxorubicin 25 mg / m2 IV on days 1-3, Cisplatin 120 mg / m2 IV on day 1 against the background of hyperhydration. G-CSF support from 4 to 13 days. Methotrexate 12 g / m2 at 28 and 35 days IV with leucovorin 60 mg / m2 in the first 5 days after each administration of methotrexate. The interval between cycles is 42 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Two-component chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Doxorubicin 25 mg / m2 IV on days 1-3, Cisplatin 120 mg / m2 IV on day 1 against the background of hyperhydration. G-CSF support from 4 to 13 days. The interval between cycles is 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin, Cisplatin, Methotrexate</intervention_name>
    <description>IV</description>
    <arm_group_label>Three-component chemotherapy</arm_group_label>
    <other_name>MAP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin, Cisplatin</intervention_name>
    <description>IV</description>
    <arm_group_label>Two-component chemotherapy</arm_group_label>
    <other_name>AP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Histologically confirmed diagnosis of primary bone tumor (osteosarcoma)&#xD;
&#xD;
        Age from 24 to 40 years&#xD;
&#xD;
        Operable process, possibility of performing resection R0-R1&#xD;
&#xD;
        ECOG performance score 0 or 1&#xD;
&#xD;
        Normal renal function (estimated creatinine clearance more than 60 ml / min)&#xD;
&#xD;
        Normal liver function (AST, ALT - no more than 3 norms)&#xD;
&#xD;
        Left ventricular ejection fraction&gt; 55%&#xD;
&#xD;
        Adequate marrow function (hemoglobin level more than 9 g / dL, neutrophil count more than&#xD;
        1.5 thousand / μl, platelet number more than 100 thousand / μl)&#xD;
&#xD;
        Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Children, women during pregnancy, childbirth, women during breastfeeding&#xD;
&#xD;
        Persons with mental disorders&#xD;
&#xD;
        The presence of an active viral infection with HIV, viral hepatitis B and C&#xD;
&#xD;
        Inoperable tumor&#xD;
&#xD;
        Morphologically confirmed diagnosis of GIST, Kaposi's sarcoma, alveolar or clear cell&#xD;
        sarcoma, chondrosarcoma, chordoma, giant cell tumor, paraosal osteosarcoma, Ewing's sarcoma&#xD;
        / PNET, rhabdomyosarcoma, G1 osteosarcoma&#xD;
&#xD;
        The presence of a second malignant neoplasm within the last 5 years before enrollment,&#xD;
        other than cured basal cell or squamous cell carcinoma or cervical cancer in situ, prostate&#xD;
        cancer&#xD;
&#xD;
        Clinically significant cardiovascular or cerebrovascular diseases within the last 6 months&#xD;
        (acute myocardial infarction, unstable angina pectoris, significant ventricular&#xD;
        arrhythmias, severe heart failure (NYHA class IV), stroke or uncontrolled arterial&#xD;
        hypertension)&#xD;
&#xD;
        Renal failure (serum creatinine level more than 150 μmol / L), except for cases caused by&#xD;
        lymphoid infiltration of the kidneys, and tumor disintegration syndrome&#xD;
&#xD;
        Hepatic failure (except for cases caused by leukemic / lymphoid organ infiltration), acute&#xD;
        hepatitis (serum bilirubin level more than 2 norms, ALT and AST activity more than 4 norms,&#xD;
        prothrombin index less than 50%)&#xD;
&#xD;
        Decompensated diabetes mellitus (blood serum glucose above 15 mmol / L)&#xD;
&#xD;
        Sepsis (septicopyemic foci, hemodynamic instability; ineffective antimicrobial therapy) or&#xD;
        acute infectious diseases&#xD;
&#xD;
        Brain metastases&#xD;
&#xD;
        Life-threatening conditions (bleeding, tumor decay, etc.)&#xD;
&#xD;
        Hypersensitivity to the active substance of the investigational drugs or any of the&#xD;
        auxiliary components or their intolerance&#xD;
&#xD;
        Surgical interventions less than 21 days before starting therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>24 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beniamin Bokhyan, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>N.N. Blokhin NMRCO</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anastasia Tararykova</last_name>
    <phone>+79175274287</phone>
    <email>anastasiatararykova@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Federal State Budgetary Institution &quot;N.N. Blokhin National Medical Research Center of Oncology&quot; оf the Ministry of Health of the Russian Federation</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <contact>
      <last_name>Anastasia Tararykova</last_name>
      <phone>89175274287</phone>
      <email>anastasiatararykova@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Anastasia Tararykova</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrei Konev</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Beniamin Bokhyan, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aslan Valiev, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>https://www.ronc.ru/about/struktura/niiko/ooo/hn1/</url>
    <description>official site</description>
  </link>
  <link>
    <url>https://sarcomarus.ru/</url>
    <description>russian surcoma group site</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 7, 2021</study_first_submitted>
  <study_first_submitted_qc>September 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2021</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bone sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Osteosarcoma</mesh_term>
    <mesh_term>Neoplasms, Connective and Soft Tissue</mesh_term>
    <mesh_term>Neoplasms, Connective Tissue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

